In all, this study expounded that Asprosin inhibition obstructed lipid accumulation and inflammatory response in NAFLD through activating AMPK signaling (Figure S2), which emphasized the significant role of Asprosin in the development of NAFLD and might provide a potential molecular target for the treatment of NAFLD. The gene discussed is FBN1; the disease is metabolic dysfunction-associated steatotic liver disease.